Pfizer and Biontech announced completing Phase 3 for their Covid vaccine on Nov 10, but their stocks showed little progress in November:
2% less than S&P 500 for PFE and 15 % more for BNTX, which, as a small company, should benefit more than that just because of lifting their brand in the spotline.
By mistake, I executed the order twice, so I bought 20 shares for $100
Leave a comment